Newly Diagnosed Multiple Myeloma

Chair(s)

• 

  Maria-Victoria Mateos, PhD (she/her/hers)

  Head of Unit
  University Hospital of Salamanca
  Salamanca, Castilla y Leon, Spain

Co-Chair(s)

• 

  S. Vincent Rajkumar, MD

  Edward W. and Betty Knight Scripps Professor of Medicine
  Mayo Clinic, Minnesota, United States

Presentations:

• 3:30 PM – 3:40 PM EEST

  What is the optimal upfront therapy - 3 or 4 drugs?
  

  Speaker: Saad Z. Usmani, MD MBA FACP – Memorial Sloan Kettering Cancer Center
• 3:40 PM – 3:50 PM EEST

  Who needs an autologous stem cell transplant upfront?
  

  Speaker: Aurore Perrot, MD, PhD – CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France
• 3:50 PM – 4:00 PM EEST

  What is the ideal duration of treatment - MRD guided or till progression?
  

  Speaker: Kwee L. Yong, PhD (she/her/hers) – University College London Cancer Institute, London, UK
• 4:00 PM – 4:10 PM EEST

  Optimizing supportive care management
  

  Speaker: Evangelos Terpos, MD, PhD (he/him/his) – Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
• 4:10 PM – 4:20 PM EEST

  OA-10: Four years treatment with Zoledronic Acid is superior to two years in protection against progressive bone disease in Multiple Myeloma
  

  Speaker: Thomas Lund, MD, PhD (he/him/his) – Department of Hematology Odense University Hospital
• 4:20 PM – 4:30 PM EEST

  OA-43: Analysis of sustained MRD-negativity and Progression-free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma – Additional Data from Planned Interim Analysis of the GMMG-CONCEPT Trial
  

  Speaker: Lisa B. Leypoldt, MD (she/her/hers) – University Medical Center Hamburg-Eppendorf, Germany / Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Department of Medicine, Harvard Medical School, Boston, MA, USA. Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
• 4:30 PM – 4:40 PM EEST

  OA-14: Persistent bone marrow and imaging MRD negativity may guide the duration of lenalidomide maintenance following ASCT in patients with multiple myeloma
  

  Speaker: Panagiotis Malandrakis, MD (he/him/his) – Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
• 4:45 PM – 5:00 PM EEST

  Discuss abstracts in context
  

  Speaker: S. Vincent Rajkumar, MD – Mayo Clinic
• 5:00 PM – 5:30 PM EEST

  Round table discussion
  

  Panelist: Sergio Giralt, MD – Memorial Sloan Kettering Cancer Center

  Panelist: Thierry Facon, MD – University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France

  Panelist: Jean-Luc Harousseau, MD – INSTITUT DE CANCEROLOGIE DE L'OUEST FRANCE

  Panelist: Vania Hungria, MD, PhD – Department of Hematology, Clinica São Germano, São Paulo, Brazil

  Panelist: Michele Cavo (he/him/his) – IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Università degli Studi di Bologna, Bologna, Italy

  Panelist: Bindu Kanapuru